NEW YORK (GenomeWeb News) – Pacific Biosciences reported after the close of the market Tuesday first-quarter revenues of $10 million, beating Wall Street's consensus estimate of $7.1 million.

The revenues compared to $270,000 in revenue for the first quarter of 2011, before the firm launched its PacBio RS system. The Q1 2012 revenues compare to fourth-quarter 2011 revenues of $12.4 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.